声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 2026年2月3日，ST未名（维权）（sz002581）触及涨停，涨停价7.55元，涨幅5.01%，总市值49.81亿 元，流通市值30.26亿元，截止发稿，总成交额2921.48万元。 根据喜娜AI异动分析，ST未名涨停原因可能如下，创新药研发+经营改善+产业链完善： 1、公司创新 药 SMR001滴眼液获 III 期临床批件，该药物针对 180 亿规模的干眼症市场，具有修复角膜神经的独特 技术优势。创新药研发的进展是刺激股价涨停的重要因素，显示公司在医药领域的技术实力和发展潜 力。 2、公司经营状况有所改善，2026 年 1 月 30 日公布 2025 年报显示亏损小幅减少，归 ...

Group 1 - Core viewpoint: Companies are announcing significant financial updates, including profit changes, new product approvals, and share repurchase plans [1][2][3][4][5][6][15] Group 2 - Company: Chip导科技 reported a revenue of 394 million yuan for 2025, a year-on-year increase of 11.52%, but a net profit of 106 million yuan, down 4.91% [1] - Company: 亿帆医药's subsidiary received a drug registration certificate for Vitamin K1 injection, which is used for treating vitamin K deficiency [2] - Company: 勤上股份 announced the termination of its share repurchase plan to stabilize stock prices [3] - Company: 极米科技 plans to repurchase shares worth between 50 million and 100 million yuan for employee stock ownership plans [4] - Company: 凌云光 intends to change the purpose of repurchased shares to cancellation, reducing total share capital from 461 million to 457 million shares [5] - Company: 苏州科达's general manager resigned, and the chairman will take over the role to ensure management continuity [6] - Company: 银轮股份 identified 徐铮铮 as a co-actual controller, following a retrospective recognition [7] - Company: 西南证券 received approval to issue bonds up to 14 billion yuan [8] - Company: 上港集团 expects a 1.3% year-on-year increase in container throughput for January [10] - Company: 宁波富达 plans to distribute a cash dividend of 0.7 yuan per 10 shares, totaling 101 million yuan [11] - Company: 协和电子 is investing 5 million yuan in a venture capital fund to enhance its understanding of high-tech industries [12] - Company: 乐鑫科技's controlling shareholder proposed a share repurchase plan of 50 million to 100 million yuan [13] - Company: 奥瑞德's subsidiary plans to invest approximately 145 million yuan in computing power equipment [14] - Company: 上汽集团 reported a 23.94% year-on-year increase in vehicle sales for January [15] - Company: 道恩股份 plans to acquire a foreign company's plastic business for 15.737 million USD [16] - Company: 红相股份 intends to transfer 100% equity of 南通瀚蓝 for 120 million yuan [17] - Company: 长龄液压 announced a tender offer to acquire 12% of its shares at 35.82 yuan per share [19] - Company: 润都股份 faces uncertainty regarding the approval of its innovative drug [20] - Company: *ST东易's asset injection plans face significant uncertainty [21] - Company: 棒杰股份 is undergoing a restructuring process that could improve its financial structure [22] - Company: 绿联科技 has submitted an application for H-share listing in Hong Kong [23] - Company: ST泉为 is facing a creditor's application for restructuring [24] - Company: 海思科's shareholders plan to reduce their holdings by up to 0.89% [25] - Company: 钧崴电子's shareholder plans to reduce holdings by up to 3% [26]

Core Viewpoint - Ruizhi Pharmaceutical (300149) expects to achieve a net profit attributable to shareholders of 12.3 million to 18.45 million yuan in 2025, marking a turnaround from losses to profitability [1] Group 1: Financial Performance - The company anticipates a net profit turnaround in 2025 due to the recovery of global innovative drug market demand [1] - The expected net profit range for 2025 is between 12.3 million yuan and 18.45 million yuan [1] Group 2: Operational Strategy - Ruizhi Pharmaceutical is leveraging its full-process R&D platform as a core competitive advantage to enhance market expansion efforts and improve order acquisition capabilities [1] - The company is implementing cost reduction and efficiency enhancement measures, leading to a decrease in period expenses and improved profitability [1] Group 3: Asset Management - In 2024, the company recorded a goodwill impairment loss of 139 million yuan, reducing the related goodwill book value to zero, which means no further goodwill impairment losses are expected in 2025 [1]

上市首日，君实生物股价最高报220.40元，为上市以来股价最高点。 君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿 元，较原计划多17.97亿元。君实生物于2020年7月8日发布的招股说明书显示，该公司计划募集资金 27.00亿元，分别用于创新药研发项目、君实生物科技产业化临港项目、偿还银行贷款及补充流动资 金。 君实生物首次公开发行股票发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。 君实生物2022年度向特定对象发行A股股票募集资金情况为，根据中国证监会出具的《关于同意上 海君实生物医药科技股份有限公司向特定对象发行股票注册的批复》（证监许可[2022]2616号），公司 获准向特定对象发行人民币普通股7,000.00万股，每股发行价格为人民币53.95元，募集资金总额为人民 币3,776,500,000.00元；扣除各项发行费用合计人民币31,697,205.06元（不含增值税）后，实际募集资金 净额为人民币3,744,802,794.94元。实际到账金额为人民币3,759,350,000.00元，包括尚未支付的其他发行 费用人民币14,547 ...

Summary of Kangyuan Pharmaceutical Conference Call Company Overview - **Company**: Kangyuan Pharmaceutical - **Industry**: Pharmaceutical, specifically focusing on traditional Chinese medicine and innovative drugs Key Points Financial Performance - In 2025, Kangyuan Pharmaceutical experienced a decline in revenue and sales profit, with net profit decreasing by 30% compared to the previous year. However, the fourth quarter saw significant growth in flu-related products and other major products, which helped narrow the overall decline in revenue and profit for the year [4][2]. Organizational Changes - The company has restructured its organization by establishing a Cardiovascular Division and a Sunshine Division. This aims to focus on the development of core products like Ginkgo and Tianshu, as well as new retail OTC channels, to promote a diverse portfolio of innovative drugs by 2026 [2][4]. Product Pipeline and Market Strategy - Kangyuan Pharmaceutical anticipates that 5 to 6 key products will likely enter the essential drug list, primarily in pediatrics and cardiovascular fields, which will help the company quickly capture market share in grassroots markets [2][5][6]. - The company is actively addressing the impact of DRG/DIP payment policies by enhancing academic promotion and advancing innovative product combinations to stabilize revenue and profit [2][13]. Clinical Trials and Innovations - The company is making progress in clinical trials for its three-target and two-target diabetes drugs, expecting to complete Phase II trials and read data by May 2026, indicating strong market potential [2][11]. - The first biological innovative drug, ZHONGXING 1,305 eye drops, is expected to be launched in 2027, with a concentrated period of innovative drug launches planned for 2028-2029 [3][15]. Regulatory Environment - The adjustment of the essential drug list policy emphasizes prioritizing innovative drugs and strengthening evidence-based medicine research. Kangyuan Pharmaceutical believes it has a competitive advantage in this area due to its commitment to clinically valuable innovation [5][9]. Market Outlook - The company aims for a rebound in 2026 after a challenging 2025, with a focus on core products and a sales strategy to achieve growth and address investor concerns [8][17]. - Kangyuan Pharmaceutical is also preparing for the commercialization of new drugs, with plans to increase R&D funding and potentially consider strategic partnerships to meet future funding needs [15]. Challenges and Opportunities - The new regulations for traditional Chinese medicine are seen as a positive signal for industry development, although they may pose risks for smaller companies. Kangyuan Pharmaceutical views this as an opportunity to increase industry concentration [9][10]. Future Expectations - Despite the setbacks in 2025, Kangyuan Pharmaceutical plans to leverage its strengths and enhance collaboration and R&D investments to achieve better results in 2026 [17]. This summary encapsulates the key insights from the conference call, highlighting the company's strategic direction, product pipeline, and market outlook.

Q4单季度有所承压，预计主要由于阶段毛利率及费用影响。 #非沙 调整即机会，Q4阶段费用扰动不改拐点趋势，持续重点推荐【天宇股份】 #Q4阶段毛利率、费用扰动，不改长期趋势。 公司发布2025年归母净利润盈利1.2亿元~1.6亿元，同比增长114.53%~186.05%。 全年维度业绩大幅增长，拐点明确，得益于非沙坦及制剂业务快速增长。 Q4单季度有所承压，预计主要由于阶段毛利率及费用影响。 #非沙坦、制剂有望保持快速增长、盈利水平加速修复，25年初以来持续推荐，逐渐跑出α。 非沙坦业务项目丰富，随着专利悬崖，仿制药订单和原研转移订单有望快速增加，接续布局的十几个项目有望快 速放量；CDMO业务持续放量，制剂业务处于快速增长通道。 前期大量产能建设已进入收获期，利用率持续爬升将带来利润率持续修复。 未来2-3年有望持续超预期，空间可观。 #沙坦业务见底、盈利触底回升、主业空间可观，沙坦价格自2021年始，经历四年下行调整，近一两年内已逐步筑 牢底部，盈利有限，行业有望逐步出清，触底回升。 调整即机会，Q4阶段费用扰动不改拐点趋势，持续重点推荐【天宇股份】 #Q4阶段毛利率、费用扰动，不改长期趋势。 公司发布2 ...

Group 1 - The company is continuously optimizing its R&D system and building an innovative ecosystem to enhance R&D efficiency and increase investment in innovative research [1] - The self-developed drug SPH3127 for hypertension has been officially approved for market launch by December 2025 [1] - Several key pipelines are progressing in clinical trials, including B001 for neuromyelitis optica, which has completed the enrollment of all key study participants, and SRD4610 for amyotrophic lateral sclerosis, which has initiated Phase III clinical trials [1]

Company Announcements - Litong Electronics clarifies that its liquid cooling product development is still in the early discussion stage, and it does not have specific plans for product development or production [2] - Changfei Fiber announces that the global fiber optic cable market environment is normal, and new products related to data centers account for a small proportion of total demand [2] - Rundu Co., Ltd. has a Class 1 innovative drug, but the approval for its injection product remains uncertain [3] - Aorui De plans to invest approximately 145 million yuan in purchasing computing power equipment [3] Investment & Contracts - Jichuan Pharmaceutical's wholly-owned subsidiary has signed an exclusive commercialization cooperation agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. [4] Equity Changes - Hongxiang Co. plans to transfer 100% equity of Nantong Hanlan to Fujian Mingao for a total price of 120 million yuan, which will help resolve historical debt issues [5] Share Buybacks - Lexin Technology plans to repurchase shares with a total amount between 50 million and 100 million yuan for employee stock ownership or equity incentive [6] - XGIMI Technology also plans to repurchase shares with a total amount between 50 million and 100 million yuan for employee stock ownership or equity incentive [7] Business Performance - Chip导科技 reports a revenue of 394 million yuan for 2025, with a net profit of 106 million yuan, reflecting a 4.91% decrease year-on-year [8] - Sainz plans to engage in molybdenum processing and sales, aiming to recover rhenium [9] - Shenghe Resources announces the unilateral termination of its strategic cooperation with ETM, and it will take legal measures to protect its rights [10] - Lianyun Technology reports a net profit growth of 20.36% for 2025, driven by increased demand for storage products [10] - Shanghai Yizhong reports a staggering net profit growth of 819.42% for 2025, attributed to the inclusion of its core product in the national medical insurance directory [11] Other News - Beiyinmei's controlling shareholder's restructuring plan has been approved by the creditors' meeting, which may lead to changes in shareholder equity [12] - Changchun High-tech's subsidiary has received acceptance for a clinical trial application for a new drug [13][14] - Dingxin Communications' vice president has been warned and fined for suspected short-term trading of company stock [15]

智通财经APP讯，润都股份(002923.SZ)发布股价异动公告称，公司目前有1类创新药(化学药)盐酸去甲 乌药碱注射液(规格：2ml:2.5mg)及其原料药，其药品审评工作正在有序进行。创新药具有研发周期 长，投入大，风险高的特点，药品能否获批上市以及获批上市的时间、上市后的生产和销售情况存在不 确定性，短期内也不会对公司业绩产生重大影响。 ...

智通财经APP讯，润都股份(002923.SZ)发布股价异动公告称，公司目前有1类创新药(化学药)盐酸去甲 乌药碱注射液(规格：2ml:2.5mg)及其原料药，其药品审评工作正在有序进行。创新药具有研发周期 长，投入大，风险高的特点，药品能否获批上市以及获批上市的时间、上市后的生产和销售情况存在不 确定性，短期内也不会对公司业绩产生重大影响。 ...